Skip to main content


Figure 4 | BMC Cancer

Figure 4

From: Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy

Figure 4

The presence of 3-hydroxybutyrate does not modify the sensitivity of LNT-229 cells to inhibitors of oxidative phosphorylation, glycolysis, TRAIL or temozolomide. LNT-229 cells (mean and standard deviation) were treated with increasing concentrations of (A) rotenone (48 h), (B) 3-bromopyruvate (150 min) or (C) TRAIL (24 h). In the 3-bromopyruvate experiments, cells were preincubated in medium containing 3-hydroxybutyrate (3OHB, 5 mM) or not. Cell density was evaluated by crystal violet staining (A, B) or MTT reduction (C). (D) LNT-229 cells were exposed to temozolomide for 24 h, followed by further observation in drug-free medium supplemented with 3-hydroxybutyrate (3OHB, 5 mM) or not, and clonogenic survival was analyzed (mean and standard deviation).

Back to article page